IP Library › Granted Patent US 12,545,910
Granted Patent B2
US 12,545,910 · App. 17/810,042 · Granted Feb 10, 2026

Compositions, systems, and methods for genome editing

Inventors: Adam Patrick Joyce (Stow, MA); Michael Andreas Kock (Rheinfelden, DE); Hannah Pham (Somerville, MA)
Assignee: INARI AGRICULTURE TECHNOLOGY, INC.
C12N15/11C12N9/22C12N15/8213C12N15/907C12N2310/20C12N2800/80
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,545,910
App. No.
17/810,042
Granted
Feb 10, 2026
Kind
B2
Abstract

This disclosure provides compositions that include a polynucleotide including or encoding a Cas12a tracrRNA, and methods for their use in sequence-specific genome editing, especially of eukaryotic genomic sequences. In particular, this disclosure provides Cas12a tracrRNA-containing compositions and methods for their use in Cas12a-mediated editing of a target sequence, wherein the editing efficiency is increased in comparison to controls lacking the Cas12a tracrRNA.

Claims (39)

1 . A method of editing a genetic locus with a Cas12a nuclease, comprising contacting DNA that comprises the genetic locus with:

(a) a Cas12a nuclease; and

(b) an engineered Cas12a crRNA that includes a spacer sequence that is designed to hybridize with a target sequence in the genetic locus; and

(c) a Cas12a tracrRNA provided in a molar amount that is at least 10-fold greater than the molar amount of the Cas12a nuclease and the engineered Cas12a crRNA,

thereby editing the genetic locus with an increased efficiency compared to when the Cas12a tracrRNA is not provided at 10-fold greater than the molar amount of the Cas12a nuclease and the engineered Cas12a crRNA.

2 . The method of claim 1 , wherein the DNA that comprises the genetic locus is:

(a) genomic nuclear DNA of a non-human animal, a human, a plant, or a fungus, or DNA of a eukaryotic organelle;

(b) in a eukaryotic DNA molecule in vitro;

(c) in a eukaryotic cell, cell line, tissue, callus, or multicellular organism.

3 . The method of claim 1 , wherein the DNA that comprises the genetic locus is in a eukaryotic cell in vitro, ex vivo, or in vivo.

4 . The method of claim 1 , wherein the Cas12a nuclease is provided:

(a) as a Cas12a nuclease protein; or

(b) as a ribonucleoprotein complex comprising the Cas12a nuclease and the engineered Cas12a crRNA; or

(c) as a polynucleotide encoding the Cas12a nuclease.

5 . The method of claim 1 , wherein the Cas12a nuclease is:

(a) a Cas12a nuclease identified from the genome of a bacterial species selected from the group consisting of Francisella tularensis 1, Prevotella albensis , Lachnospiraceae bacterium MC2017 1, Butyrivibrio proteoclasticus , Peregrinibacteria bacterium GW2011_GWA2 33 10, Parcubacteria bacterium GW2011_GWC2_44_17 , Smithella sp. SCADC, Acidaminococcus sp. BV3L6, Lachnospiraceae bacterium MA2020 , Candidatus Methanoplasma termitum, Eubacterium eligens, Moraxella bovoculi 237 , Leptospira inadai , Lachnospiraceae bacterium ND2006, Porphyromonas crevioricanis 3, Prevotella disiens and Porphyromonas macacae ; or

(b) a Cas12a nuclease selected from the group consisting of LbCas12a, AsCas12a, FnCas12a, and a deactivated Cas12a nuclease; or

(c) a Cas12a nuclease having at least 80% sequence identity with a sequence selected from the group consisting of SEQ ID NOs: 11, 107-138, 172, 204-221, and 222; or

(d) a Cas12a nuclease variant selected from the group consisting of (1) a variant LbCpf1 that differs from a wild-type LbCpf1 sequence (SEQ ID NO:135) in containing at least one point mutation selected from the group consisting of G309P, Y312F, M474I, D523N, Q531K, C930A, D937N, V954F/Q, M975L, A984E, 1994L, T1006K, I1014V, V1055N/D, L1065F/Y, Y1180F, V1209G, I1229L, V801I, Y802I, D850A, E943A, and D1198A; (2) a variant AsCpf1 that differs from a wild-type AsCpf1 sequence (SEQ ID NO:134) in containing at least one point mutation selected from the group consisting of L320P, V980A, Q987N, T1004F/Q, K1035E, T1057K, D1107N, F1117Y, N1291L, D908A, E993A, and D1263A; (3) a variant FnCpf1 that differs from a wild-type FnCpf1 sequence (SEQ ID NO:172) in containing at least one point mutation selected from the group consisting of 1339P, L342F, Q588K, F1017Q, K1047E, N1118D, F1128Y, L867I, D917A, E1006A, and D1255A; and (4) a variant ObCsm1 sequence that differs from a wildtype ObCsm1 sequence (SEQ ID NO:137) in containing at least one point mutation selected from the group consisting of K382N, Q393K, S925A, E933N, K943F/Q, K972L, K1064G, P670I, N671I, D727A, E939A, and D1053A.

6 . The method of claim 1 , wherein the Cas12a tracrRNA is provided:

(a) as DNA encoding a first RNA molecule comprising the Cas12a tracrRNA and comprising a restriction endonuclease cleavage site that is suitable for insertion of a sequence coding for a functional RNA moiety; or

(b) as a functional RNA molecule comprising the Cas12a tracrRNA and a functional RNA moiety, or as a polynucleotide encoding the functional RNA molecule; or

(c) by a DNA expression system comprising (i) DNA sequence for a first promoter; and (ii) operably linked and heterologous to the first promoter, DNA encoding a first RNA molecule comprising a Cas12a tracrRNA and comprising a restriction endonuclease cleavage site that is suitable for insertion of a sequence coding for a functional RNA moiety; and (iii) optionally, a terminator 3′ to and operably linked to the DNA encoding the first RNA molecule; or

(d) by a DNA expression system comprising: (i) DNA sequence for a first promoter; and (ii) operably linked and heterologous to the first promoter, a DNA encoding a functional RNA molecule comprising a Cas12a tracrRNA and a functional RNA moiety; and (iii) optionally, a terminator 3′ to and operably linked to the DNA encoding a functional RNA molecule; or

(e) as a Cas12a tracrRNA synthesized in vitro; or

(f) as a Cas12a tracrRNA obtained from a naturally occurring source.

7 . The method of claim 1 , wherein the Cas12a tracrRNA:

(a) is identified from the same genomic region as the Cas12a nuclease by at least the following steps:

(i) identifying in the genomic region flanking the DNA encoding the Cas12a nuclease at least one nucleotide sequence that comprises a CRISPR array including direct repeats; and

(ii) identifying as a putative Cas12a tracrRNA at least one nucleotide sequence in either the sense or antisense direction in the genomic region flanking the DNA encoding the Cas12a nuclease, wherein the putative Cas12a tracrRNA has a nucleotide sequence that has at least 50% complementarity with the nucleotide sequence of the direct repeat;

or

(b) has a nucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NOs: 1, 3, 6, 139-146, 149-169, 223-240, and 241.

8 . The method of claim 1 , wherein the Cas12a tracrRNA has a nucleotide sequence having sufficient complementarity to the engineered Cas12a crRNA's 3′ extension to allow hybridization between the tracrRNA and the engineered Cas12a crRNA.

9 . The method of claim 1 , wherein the engineered Cas12a crRNA, or a polynucleotide encoding the engineered Cas12a crRNA, further comprises at least one direct repeat sequence or fragment thereof capable of associating with the Cas12a nuclease adjacent to and 3′ to the spacer sequence.

10 . The method of claim 1 , wherein the engineered Cas12a crRNA further comprises a 3′ extension adjacent to the spacer sequence.

11 . The method of claim 1 , wherein the editing of the genetic locus is:

(a) effecting an indel in the genetic locus; or

(b) effecting non-homologous end joining (NHEJ) in the genetic locus; or

(c) effecting homology-dependent repair (HDR) in the genetic locus.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 7, 2023
From: JOYCE, ADAM PATRICK; KOCK, MICHAEL ANDREAS; PHAM, HANNAH
To: INARI AGRICULTURE TECHNOLOGY, INC.
Reel/Frame 062615/0106 →
Continuity (3)
Continuation In Part 16557566 · Aug 30, 2019
Provisional Application 62725910 · Aug 31, 2018
Related Publication 20220333101A1 · Oct 20, 2022
References Cited (61)
US 8697359B1 · Zhang · 2014 [cited by applicant]
US 8771945B1 · Zhang · 2014 [cited by applicant]
US 8795965B2 · Zhang · 2014 [cited by applicant]
US 8865406B2 · Zhang et al. · 2014 [cited by applicant]
US 8871445B2 · Cong et al. · 2014 [cited by applicant]
US 8889356B2 · Zhang · 2014 [cited by applicant]
US 8889418B2 · Zhang et al. · 2014 [cited by applicant]
US 8895308B1 · Zhang et al. · 2014 [cited by applicant]
US 8906616B2 · Zhang et al. · 2014 [cited by applicant]
US 8932814B2 · Cong et al. · 2015 [cited by applicant]
US 8945839B2 · Zhang · 2015 [cited by applicant]
US 8993233B2 · Zhang et al. · 2015 [cited by applicant]
US 8999641B2 · Zhang et al. · 2015 [cited by applicant]
US 9790490B2 · Zhang et al. · 2017 [cited by applicant]
US 9896696B2 · Begemann et al. · 2018 [cited by applicant]
US 11459551B1 · Joyce et al. · 2022 [cited by applicant]
US 11479762B1 · Joyce et al. · 2022 [cited by applicant]
US 20150059010A1 · Cigan et al. · 2015 [cited by applicant]
US 20150082478A1 · Cigan et al. · 2015 [cited by applicant]
US 20150344912A1 · Kim · 2015 [cited by applicant]
US 20160138008A1 · Doudna · 2016 [cited by applicant]
US 20160208243A1 · Zhang et al. · 2016 [cited by applicant]
US 20180187176A1 · Behlke et al. · 2018 [cited by applicant]
US 20200263190A1 · Zhang et al. · 2020 [cited by applicant]
US 20220348910A1 · Gonatopoulos-Pournatzis et al. · 2022 [cited by applicant]
CN 113604608A · 2021 [cited by applicant]
WO 2016166340A1 · 2016 [cited by applicant]
WO 2018208755A1 · 2018 [cited by applicant]
WO 2021154866A1 · 2021 [cited by applicant]
WO 2022159402A1 · 2022 [cited by applicant]
Extended European Search Report in EP22182273.7, mailed Mar. 13, 2023, 16 pages. [cited by applicant]
Wang et al., “A microRNA-inducible CRISPR-Cas9 platform serves as a microRNA sensor and cell-type-specific genome regulation tool,” Nature Cell Biology, Apr. 2019, vol. 21, pp. 522-530. [cited by applicant]
Invitation to Pay Additional Fees in PCT/US2022/073286, mailed Mar. 14, 2023, 12 pages. [cited by applicant]
Zetschte et al, “Cpf1 is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System” Cell, pp. 759-771, vol. 163, Elsevier Inc., Oct. 22, 2015. [cited by applicant]
Begemann et al., “Characterization and Validation of a Novel Group of Type V, Class 2 Nucleases for in vivo Benome Editing”, bioRxiv, 2017, pp. 1-9, hllps://doi.org/10.1101/192799. [cited by applicant]
Burstein et al., “New CRISPR-Cas Systems from Uncultivated Microbes”, published as Nature, 2017, pp. 237-241, vol. 542, No. 7640 doi: 10.1038/nature21059. [cited by applicant]
Cong et al., “Multiplex Genome Engineering Using CRISPR/Cas Systems”, Science, 2013, pp. 819-823, vol. 339, No. 6121. [cited by applicant]
Di Tomasso et al., “The ARiBo Tag: A Reliable Tool for Affinity Purification of RNAs under Native Conditions”, Nucleic Acids Research, 2011, pp. 1-10, vol. 39, No. 3, e18. [cited by applicant]
Hendel et al., “Chemically Modified Guide RNAs Enhance CRISPR-Cas Genome Editing in Human Primary Cells”, published as Nature Biotechnology, 2015, pp. 985-989, vol. 33, No. 9. [cited by applicant]
Kieft et al., “A General Method for Rapid and Nondenaturing Purification of RNAs”, RNA, 2004, pp. 988-995, vol. 10. [cited by applicant]
Lee et al., “RNA-protein Analysis Using a Conditional CRISPR Nuclease”, Proceedings of the National Academy of Sciences USA, Apr. 2013, pp. 5416-5421, vol. 110, No. 14. [cited by applicant]
Leppek et al., “An Optimized Streptavidin-Binding RNA Aptamer for Purification of Ribonucleoprotein Complexes Identifies Novel ARE-Binding Proteins”, Nucleic Acids Research, 2014, pp. 1-15, vol. 42, No. 2. [cited by applicant]
Park et al., “Extension of the crRNA Enhances Cpf1 Gene Editing in vitro and in vivo”, Nature Communications, 2018, pp. 1-12, doi: 10.1038/s41467-018-05641-3. [cited by applicant]
Parrott et al., “RNA Aptamers for the MS2 Bacteriophage Coat Protein and the Wild-Type RNA Operator have Similar Solution Behaviour”, Nucleic Acids Research, 2000, pp. 489-497, vol. 28, No. 2. [cited by applicant]
Ran et al., “Genome Engineering Using the CRISPR-Cas9 System”, Nature Protocols, 2013, pp. 2281-2308, vol. 8, No. 11. [cited by applicant]
Shmakov et al., “Discovery and Functional Characterization of Diverse Class 2 CRISPR-Cas Systems”, Molecular Cell, 2015, pp. 385-397, vol. 60. [cited by applicant]
Srisawat et al., “RNA Affinity Tags for Purification of RNAs and Ribonucleoprotein Complexes”, Methods, Feb. 2002, pp. 156-161, vol. 26, No. 2. [cited by applicant]
Sternberg et al. (DNA interrogation by the CRISPR RNA-guided endonuclease Cas9, Nature. Mar. 6, 2014; 507 (7490): 62-67) ( Year: 2014). [cited by applicant]
International Search Report in PCT/US22/73286, mailed May 11, 2023. [cited by applicant]
International Search Report in PCT/US22/73281, mailed May 11, 2023. [cited by applicant]
Extended European Search Report in EP22182278.6, mailed Dec. 15, 2022, 12 pages. [cited by applicant]
Gonatopoulos-Pournatzis et al., “Genetic interaction mapping and exon-resolution funtional genomics with a hybrid Cas9-Cas12a platform,” Nature Biotechnology, May 2020, vol. 38, pp. 638-648. [cited by applicant]
Jedrzejczyk et al., “CRISPR-Cas12a Nucleases Function with Structurally Engineered crRNAs—Synthetic trAcrRNA,” Research Square, Oct. 21, 2021, 30 pages. [cited by applicant]
Zetsche et al., “Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System,” Cell, Oct. 22, 2015, vol. 163, pp. 759-771. [cited by applicant]
Sternberg et al., “DNA interrogation by the CRISPR RNA-guided endonuclease Cas9,” Nature, Mar. 6, 2014, vol. 507, No. 7490, pp. 62-67, 18 pages. [cited by applicant]
Gier et al., “High-performance CRISPR-Cas12a genome editing for combinatorial genetic screening,” Nature Communications, Jul. 13, 2020, vol. 11, No. 1, pp. 1-10. [cited by applicant]
Bandyopadhyay et al., “CRISPR-Cas12a (Cpf1): A Versatile Tool in the Plant Genome Editing Tool Box for Agricultural Advancement,” Frontiers in Plant Science, Nov. 2020, vol. 11, Article No. 584151, pp. 1-18. [cited by applicant]
Teng et al., “Enhanced mammalian genome editing by new Cas 12a orthologs with optimized crRNA scaffolds,” Genome Biology, 2019, vol. 20, No. 15, pp. 1-6. [cited by applicant]
Dai et al., “One-step generation of modular CAR-T cells with AAV-Cpf1,” Nature Methods, Mar. 2019, vol. 16, pp. 247-254. [cited by applicant]
Partial European Search Report in EP22182273.7, mailed Dec. 21, 2022, 15 pages. [cited by applicant]
Oh et al., “Multiplex gene targeting in the mouse embryo using a Cas9-Cpf1 hybrid guide RNA,” Biochemical and Biophysical Research Communications, 2021, vol. 539, pp. 48-55. [cited by applicant]